Five Prime Therapeutics, Inc.

Bristol-myers Squibb Compnay

Glaxosmithkline Intellectual Property (no.2) Limited

Glaxosmithkline Intellectual Property Limited

David Bellovin

Brian Wong

Emma Masteller

Katherine E Lewis

Kevin Hestir

Thomas Brennan

Julie Hambleton

Robert Sikorski

Barbara Sennino

David Busha

Kevin P Baker

Nels P Nielson

Kathy Miller

Maike Schmidt

Luis Borges

Majid Ghoddusi

Charles Kaplan

Derrick Houser

Gloria Brattich

Felicia Kemp

Ernestine A Lee

Rakesh Kumar

Janine Powers

Penny E Phillips

Michael Carleton

Bijoyesh Mookerjee

Maurice P DeYoung

Arundathy Nirmalini Pandite

Serena Kimi Perna

Ke Xu

Dimple Pandya

Maurice P Deyoung

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.

CD80 extracellular domain polypeptides and their use in cancer treatment

B7-H4 antibodies and methods of use thereof

Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers

Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.

Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer

The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).

Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer

This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer

Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.

Methods of treating mesothelioma by administration of compounds comprising FGFR1 ECD

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Growing community of inventors

San Jose, CA, United States of America

David Bellovin